Historically, the synthetic lethality achieved through PARP inhibition in BRCA1/2 mutated breast cancer represents the ideal scenario for DDR inhibitor monotherapy; however, PARP inhibition is applicable outside of BRCA1/2 mutated cancers (16). Here, PARP1 is linked to breast carcinoma.